227 related articles for article (PubMed ID: 9194473)
1. Preclinical, pharmacologic, and phase I studies of gemcitabine.
Storniolo AM; Allerheiligen SR; Pearce HL
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-2-S7-7. PubMed ID: 9194473
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of gemcitabine in lung cancer: part I.
Bunn PA
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-1. PubMed ID: 9194472
[No Abstract] [Full Text] [Related]
3. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine: a cytidine analogue active against solid tumors.
Hui YF; Reitz J
Am J Health Syst Pharm; 1997 Jan; 54(2):162-70; quiz 197-8. PubMed ID: 9117804
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
Hansen HH; Sørensen JB
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-38-S7-41. PubMed ID: 9194478
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine--a major advance?
Thomas A; Steward WP
Ann Oncol; 1998 Dec; 9(12):1265-7. PubMed ID: 9932153
[No Abstract] [Full Text] [Related]
8. Gemcitabine: safety profile unaffected by starting dose.
Martin C; Pollera CF
Int J Clin Pharmacol Res; 1996; 16(1):9-18. PubMed ID: 9001925
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine: preclinical pharmacology and mechanisms of action.
Plunkett W; Huang P; Searcy CE; Gandhi V
Semin Oncol; 1996 Oct; 23(5 Suppl 10):3-15. PubMed ID: 8893876
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and UFT plus oral calcium folinate: phase I study.
Philip PA; Ibrahim D; Zalupski M; Arlauskas P; Shields A
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):116-9. PubMed ID: 10442378
[TBL] [Abstract][Full Text] [Related]
11. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A; Gridelli C; De Marinis F; Fabi A; Gamucci T; Cortesi E; Barduagni M; Antimi M; Maione P; Migliorino MR; Giannarelli D; Cognetti F
Cancer; 2003 Jul; 98(2):337-43. PubMed ID: 12872354
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine--status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Symposium proceedings. Amsterdam, The Netherlands, March 15, 1994.
Semin Oncol; 1995 Aug; 22(4 Suppl 11):1-82. PubMed ID: 7481838
[No Abstract] [Full Text] [Related]
13. Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer.
Sandler A; Ettinger DS
Oncologist; 1999; 4(3):241-51. PubMed ID: 10394591
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
Thatcher N; Jayson G; Bradley B; Ranson M; Anderson H
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-6-S8-12. PubMed ID: 9207309
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
[TBL] [Abstract][Full Text] [Related]
18. [New antitumor antimetabolites--gemcitabine and DMDC].
Matsui K; Fukuoka M
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2127-32. PubMed ID: 1332622
[TBL] [Abstract][Full Text] [Related]
19. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine in the treatment of non-small-cell lung cancer.
Burkes RL; Shepherd FA
Ann Oncol; 1995; 6 Suppl 3():S57-60. PubMed ID: 8616118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]